ArticleCase reports in infectious diseases2026
Beyond 'One Size Fits All': Abatement of Linezolid-Induced Thrombocytopenia Through Therapeutic Drug Monitoring and Precision Dosing-A Case Study.
Article in Case reports in infectious diseases, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Beyond 'One Size Fits All': Abatement of Linezolid-Induced Thrombocytopenia Through Therapeutic Drug Monitoring and Precision Dosing-A Case Study.Case reports in infectious diseases · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Linezolid is an oxazolidinone antibiotic used in the treatment of Gram-positive bacterial infections. However, its prolonged use is often limited by adverse effects, including thrombocytopenia. Therapeutic drug monitoring (TDM) has been proposed to individualize linezolid dosing to mitigate such adverse effects. This study presents a case of linezolid-induced thrombocytopenia successfully managed with TDM and dose individualization in a patient receiving linezolid as chronic suppressive therapy for cardiac implantable electronic device (CIED) infection. Methods: A 92-year-old female with a history of recurrent Results: Upon initiation of linezolid (600 mg daily), the patient's baseline platelet count was 150 × 10 Conclusion: This case highlights the utility of TDM in managing linezolid-induced thrombocytopenia, particularly in patients requiring prolonged therapy. TDM enabled precise dose adjustments, ensuring therapeutic efficacy while minimizing toxicity. The findings support the broader implementation of TDM in linezolid therapy to enhance patient safety and treatment outcomes, particularly in long-term therapy or deep-seated infections.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.